ArticleAIDS research and therapy2025
Attitudes and eligibility of long-acting cabotegravir/rilpivirine treatment among youth living with HIV in a clinical and national cohort in Thailand: a cross-sectional study.
Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Willingness to switch to long-acting regimens among people with HIV: a systematic review and meta-analysis.AIDS (London, England) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-acting cabotegravir/rilpivirine (LA-CAB/RPV) is the only available approved injectable antiretroviral therapy (ART) for youth living with HIV (YLHIV). However, it is not yet available through the Thai National AIDS Program (NAP). This study assessed Thai YLHIV attitudes toward LA-CAB/RPV and identified the proportion of medically eligible YLHIV within the NAP.
methodsTwo cross-sectional studies were conducted, the first study conducted in an HIV clinic in Bangkok involving YLHIV aged 13-24 years, assessing attitudes via questionnaires. The second study analyzed medical eligibility among 14,670 youth aged 12-24 years in the NAP, defined by current HIV RNA < 50 copies/ml, no prior treatment failure (HIV RNA < 1,000 copies/ml) and no suspected archived resistance to CAB/RPV. Logistic regression was performed to identify factors associated with willingness and eligibility.
resultsFrom April to June 2024, 100 YLHIV (median age 20 years; IQR 19.0-21.7) were enrolled, 71% had non-perinatally acquired HIV (non-PHIV). Overall, 85% expressed willingness to use LA-CAB/RPV. Non-PHIV youth showed significantly higher interest (93.0% vs. 65.5%); OR 6.9 [95% CI: 2.1-22.8], despite a shorter median treatment duration (2.7 vs. 14.3 years). LA-CAB/RPV was considered more convenient than pills by 76%, although 42% anticipated injection-site reactions. Among YLHIV in the NAP (median age 22 years; IQR 20-23), 64% were medically eligible, non-PHIV youth also had a higher eligibility proportion (70% vs. 32%) with an aOR 2.0 [95% CI: 1.7-2.4].
conclusionThe majority of Thai YLHIV showed positive attitudes towards LA-CAB/RPV, with two-thirds meeting medical eligibility criteria. Enhancing access to generic formulations of this regimen could significantly impact lifelong HIV management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.